Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

Coeptis Therapeutics Holdings (COEPW) Total Non-Current Liabilities (2021 - 2025)

Historic Total Non-Current Liabilities for Coeptis Therapeutics Holdings (COEPW) over the last 5 years, with Q3 2025 value amounting to $559500.0.

  • Coeptis Therapeutics Holdings' Total Non-Current Liabilities rose 491.2% to $559500.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $559500.0, marking a year-over-year increase of 491.2%. This contributed to the annual value of $528125.0 for FY2024, which is 3127.21% down from last year.
  • According to the latest figures from Q3 2025, Coeptis Therapeutics Holdings' Total Non-Current Liabilities is $559500.0, which was up 491.2% from $636124.0 recorded in Q2 2025.
  • Over the past 5 years, Coeptis Therapeutics Holdings' Total Non-Current Liabilities peaked at $4.1 million during Q3 2022, and registered a low of $337999.0 during Q1 2025.
  • Moreover, its 5-year median value for Total Non-Current Liabilities was $1.5 million (2021), whereas its average is $1.6 million.
  • In the last 5 years, Coeptis Therapeutics Holdings' Total Non-Current Liabilities skyrocketed by 8045.86% in 2022 and then tumbled by 8689.49% in 2023.
  • Coeptis Therapeutics Holdings' Total Non-Current Liabilities (Quarter) stood at $1.6 million in 2021, then dropped by 21.83% to $1.3 million in 2022, then plummeted by 40.42% to $768429.0 in 2023, then plummeted by 31.27% to $528125.0 in 2024, then increased by 5.94% to $559500.0 in 2025.
  • Its last three reported values are $559500.0 in Q3 2025, $636124.0 for Q2 2025, and $337999.0 during Q1 2025.